Author:
Vasterling Megan E,Maitski Rebecca J,Davis Brice A,Barnes Julie E,Kelkar Rucha A,Klapper Rachel J,Patel Hirni,Ahmadzadeh Shahab,Shekoohi Sahar,Kaye Alan D,Varrassi Giustino
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Prevalence of Duchenne and Becker muscular dystrophies in the United States;Romitti PA;Pediatrics,2015
2. Duchenne Muscular Dystrophy;Venugopal V,2023
3. AMONDYS 45 (Casimersen). Prescribing information. (2021). https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213026lbl.pdf.
4. Anti-RANKL therapy prevents glucocorticoid-induced bone loss and promotes muscle function in a mouse model of Duchenne muscular dystrophy;Jayash SN;Calcif Tissue Int,2023
5. Dystrophinopathies Treatment & Management. (2023). https.//emedicine.medscape.com/article/1173204-treatment?form=fpf.